Multi-drug resistant Mycobacterium tuberculosis in Port Harcourt, Nigeria
- PMID: 30568903
- PMCID: PMC6295751
- DOI: 10.4102/ajlm.v7i2.805
Multi-drug resistant Mycobacterium tuberculosis in Port Harcourt, Nigeria
Abstract
Background: In past years, much focus has been on tackling the scourge and spread of tuberculosis worldwide. The recent emergence of multi-drug resistant (MDR) tuberculosis has, however, negatively threatened progress made so far. Nigeria ranks fourth out of the 22 high tuberculosis burden countries in the world and has the highest burden of tuberculosis in Africa. It is therefore necessary to monitor the MDR tuberculosis situation in the country.
Objectives: This study set out to assess the proportions of MDR tuberculosis in patients attending six directly observed treatment short-course centres in Port Harcourt, Nigeria, from October 2015 to October 2016.
Methods: Six hundred and nine participants between the ages of 18 and 75 years were enrolled in this study and comprised suspected and newly diagnosed tuberculosis cases. Sputum samples obtained from the participants were screened for the presence of Mycobacterium tuberculosis using standard culture and phenotypic biochemical techniques, and drug susceptibility testing was carried out using the 1% proportion conventional method.
Results: Of the 609 participants enrolled, 30 (4.9%) were confirmed as M. tuberculosis-positive cases. A high prevalence of drug resistant tuberculosis was noted in this study (14/30, 46.7%), with 26.7% of isolates resistant to streptomycin. MDR tuberculosis, defined as being resistant to isoniazid and rifampicin, was detected in only one case (3.3%).
Conclusion: This study reports a low rate of MDR tuberculosis and contributes to the sparse data on drug resistant tuberculosis in Nigeria.
Conflict of interest statement
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Figures
Similar articles
-
Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients Attending Chest Clinics in Osun-State, Nigeria.Curr Pharm Biotechnol. 2020;21(10):939-947. doi: 10.2174/1389201021666200226100242. Curr Pharm Biotechnol. 2020. PMID: 32101120
-
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.J Assoc Physicians India. 2006 Mar;54:219-34. J Assoc Physicians India. 2006. PMID: 16800350
-
Isolation of Mycobacterium tuberculosis from sputum of tribal, non-tribal pulmonary tuberculosis patients of Andaman & Nicobar islands by conventional culture method and assessment of first line anti-tuberculosis drug susceptibility patterns.Indian J Tuberc. 2015 Jan;62(1):23-8. doi: 10.1016/j.ijtb.2015.02.004. Epub 2015 Mar 7. Indian J Tuberc. 2015. PMID: 25857562
-
The management of tuberculosis: epidemiology, resistance and monitoring.Dan Med Bull. 2010 Nov;57(11):B4213. Dan Med Bull. 2010. PMID: 21055374 Review.
-
[Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].Kekkaku. 2001 Jan;76(1):33-43. Kekkaku. 2001. PMID: 11211781 Review. Japanese.
Cited by
-
Differential yield of universal versus selective drug susceptibility testing of patients with tuberculosis in high-burden countries: a systematic review and meta-analysis.BMJ Glob Health. 2020 Oct;5(10):e003438. doi: 10.1136/bmjgh-2020-003438. BMJ Glob Health. 2020. PMID: 33037062 Free PMC article.
-
Rifampicin-resistant Mycobacterium tuberculosis and unsuccessful results from Xpert® MTB/Rif-Ultra assay in Amhara Region, Ethiopia.J Clin Tuberc Other Mycobact Dis. 2025 Apr 25;40:100528. doi: 10.1016/j.jctube.2025.100528. eCollection 2025 Aug. J Clin Tuberc Other Mycobact Dis. 2025. PMID: 40351513 Free PMC article.
-
Antimicrobial resistance surveillance in Africa: Successes, gaps and a roadmap for the future.Afr J Lab Med. 2018 Dec 6;7(2):924. doi: 10.4102/ajlm.v7i2.924. eCollection 2018. Afr J Lab Med. 2018. PMID: 30568909 Free PMC article. No abstract available.
-
Medication Adherence among Pulmonary Tuberculosis Patients in Treatment Centers in a Southern Nigerian Local Government Area: Question Mark on Performance of DOTS Services.Niger Med J. 2023 Feb 24;63(5):418-424. eCollection 2022 Sep-Oct. Niger Med J. 2023. PMID: 38867749 Free PMC article.
-
Epidemiological Characteristics and Risk Factors Related to Drug-resistant Tuberculosis in Luanda, Angola.Am J Trop Med Hyg. 2022 Jan 10;106(3):779-784. doi: 10.4269/ajtmh.21-0659. Am J Trop Med Hyg. 2022. PMID: 35008058 Free PMC article.
References
-
- GBD Tuberculosis Collaborators The global burden of tuberculosis: Results from the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;18(3):261–284. https://doi.org/10.1016/S1473-3099(17)30703 - DOI - PMC - PubMed
-
- Glaziou P, Sismanidis C, Floyd K, Raviglione M. Global epidemiology of tuberculosis. Cold Spring Harb Perspect Med. 2015;5(2):a017798 https://doi.org/10.1101/cshperspect.a017798 - DOI - PMC - PubMed
-
- World Health Organization The global tuberculosis report: 2016 [homepage on the Internet]. Geneva, Switzerland: WHO; 2016. [cited 2016 Feb 9]. Available from: http://www.who.int/tb/publications/global_report/en/
-
- Farley JE, Ram M, Pan W, et al. . Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One. 2011;6(7):e20436 https://doi.org/10.1371/journal.pone.0020436 - DOI - PMC - PubMed
-
- Goyal V, Kadam V, Narang P, Singh V. Prevalence of drug-resistant pulmonary tuberculosis in India: Systematic review and meta-analysis. BMC Public Health. 2017;17(1):817 https://doi.org/10.1186/s12889-017-4779-5 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous